Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Northern Europe Keeps Up The Pressure On Biosimilar Infliximab Switching

This article was originally published in Scrip

Executive Summary

Northern European efforts to boost the use of biosimilar infliximab rather than Janssen's Remicade are gathering pace, with the Norwegian NOR-SWITCH study having been extended by 26 weeks to complete the switch from Remicade to Celltrion's biosimilar, Remsima, and a number of similar studies being conducted by both industry and non-commercial sponsors in the Netherlands.


Related Content

Remsima Stars In Orion Pharma’s First Half


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts